文献速递临床试验与 GCP流行病学与生物统计

大流行中的疫苗试验:伦理困境的潜在解决路径

Vaccine trials during a pandemic: potential approaches to ethical dilemmas.
PubMed 文献 · Trials · 2021-09-15

本文讨论新冠疫苗试验中两个主要伦理困境:成功候选疫苗出现后继续新疫苗试验的均势问题,以及盲法安慰剂对照的不伤害问题。作者提出六种潜在应对策略,并为疫苗试验后期相关方提出决策算法,强调疫情紧急性不构成妥协核心伦理价值的理由。

要点

  • 成功疫苗出现后继续新疫苗试验的均势伦理困境需审慎评估
  • 盲法安慰剂对照的不伤害问题需通过设计调整加以解决
  • 提出六种策略与决策算法供疫苗试验后期相关方参考

核心结论

  • 新冠疫苗试验面临均势与盲法安慰剂不伤害两大伦理困境,需通过多种策略调整设计以兼顾伦理与临床成功。
  • 疫情紧急性不构成妥协核心伦理价值的理由,相关讨论与决策将为未来类似场景提供案例参考。

研究设计与样本

  • 本文为综述性文章,讨论新冠疫苗试验中的伦理困境及潜在应对策略,未报告系统检索范围或样本量。

主要发现

  • 疫苗开发与社区关系密切,加速研发加剧了社区不信任与学术争议的伦理困境。
  • 作者识别两个主要伦理困境:成功候选疫苗出现后继续新疫苗试验的均势问题,以及盲法安慰剂对照的不伤害问题。

关键数值与推荐

  • 提出六种潜在策略:继续安慰剂对照试验、从安慰剂对照转为开放标签、仅对高风险优先组揭盲、转为盲法阶梯楔形交叉设计、转为盲法活性对照阶梯楔形交叉试验、开展随机阶梯楔形社区试验。
  • 提出针对疫苗试验后期相关方的决策算法。

临床怎么用

  • 相关方在疫苗试验后期可参考决策算法,根据伦理困境选择合适的设计调整策略。
  • 在疫情紧急情况下仍需坚持核心伦理价值,审慎评估继续试验与揭盲的时机与范围。

局限性

  • 本文未报告系统检索范围、样本量或定量数据,属于观点性讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ever since the emergence of the coronavirus disease 2019 (COVID-19), global public health infrastructures and systems, along with community-wide collaboration and service, have risen to an unprecedented challenge. Vaccine development was immediately propelled to the centre of all our scientific, public health and community efforts. Despite the development of SARS-CoV-2 vaccines arguably being the greatest and most palpable achievements of the past 12 months, they have also been one of the most contentious and debated issues during the pandemic. However, what uniquely differentiates vaccine development is its intimate relationship with the community it seeks to serve; both in its clinical trial testing as an efficacious and safe prophylactic, and its post-developmental 'roll-out' success, as an effective public health tool. These relationships have birthed a myriad of complexities, from community-based mistrust, to academically contended ethical dilemmas. Indeed, the accelerated advances in the COVID-19 vaccine race have further exacerbated this phenomenon, bringing with it new ethical dilemmas that need to be examined to ensure the continued clinical success of these therapeutics and a renewed societal trust in clinical medicine.In this paper, we discuss two major ethical dilemmas: (1) the equipoise of continuing new vaccine trials in the advent of successful candidates and (2) the maleficence of blinded placebo arms. Accordingly, we discuss six different potential approaches to these ethical dilemmas: (1) continuing with placebo-controlled trials, (2) transitioning from placebo-controlled to open-label, (3) unblinding at-risk priority groups only, (4) transitioning to a blinded stepped-wedge cross-over design, (5) progressing to a blinded active-controlled stepped-wedge cross-over trial, and (6) conducting randomised stepped-wedge community trials. We also propose a decision-making algorithm for relevant stakeholders in advanced stages of vaccine trials.It is important to remember that the emergent nature of the COVID-19 situation does not justify a compromise on core ethical values. In fact, the discourse surrounding this topic and the decisions made will remain a potent case study and a continuously referenced example for all such future scenarios.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Alqahtani M, Mallah SI, Stevenson N, et al. Vaccine trials during a pandemic: potential approaches to ethical dilemmas. Trials. 2021. PMID: 34526086. doi:10.1186/s13063-021-05597-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。